Patent cliff

56
CLIFF

description

patent cliff 2012-2015

Transcript of Patent cliff

Page 1: Patent cliff

CLIFF

Page 2: Patent cliff

PATENT CLIFF(2012-2015)

Presentation byPeruka Venkata Ramana Prasad

1st Semester, MBA(Pharm)Department Of Pharmaceutical Management

NIPER

Page 3: Patent cliff

What is patent cliff

Global blockbusters by revenue& patent expiration

Global drug sales at risk from patent expiration

Fall down of companys annual revenue

Key drugs in pipeline

Frequency of NME approvals may come down

Big pharma job cuts announced since 2009

FLOW OF PRESENTATION

Page 4: Patent cliff

Increasing merges &acquisitions

Hatch-waxman act-1984

Patent exclusivity & generic entry regulations

Generics will dominate the market

ENTERING “pharmering markets”

Patent wars

Contd..

Page 5: Patent cliff

It is most often described as an industry-wide expiration of the patents of a number of

blockbuster drugs with a combined of $250 billion in annual sales will go off-patent by 2015, creating

a life-threatening situation for many of the top companies in pharma sector

WHAT IS PATENT CLIFF

Source : Evaluate Pharma,2012

Page 6: Patent cliff

Other sectors, such as software and consumer goods, have patents. But they rely on rapid innovation to maintain sales.In pharmaceuticals, stringent regulations on

authorization and marketing impose tighter controls, higher costs and longer lead times, making drug developers more reliant on patent monopolies to recoup their costs

Why only pharma field is more worried?

Page 7: Patent cliff

KEY GLOBAL PLAYERS

Source : Individual company financials online 2012

Page 8: Patent cliff

GLOBAL BLOCKBUSTERS BY REVENUE&PATENT EXPIRATION

Source : Bioassociate Consulting & Management Ltd

Page 9: Patent cliff

Source : Evaluate Pharma,2012

Page 10: Patent cliff

2012 2013

2014 2015

Patent Expiration Of Drugs By Year

Page 11: Patent cliff

Source : IMS Global Insight, 2011

Page 12: Patent cliff

Source : IMS Global Insight, 2011

2013

Page 13: Patent cliff

Source : IMS Global Insight, 2011

2014

Page 14: Patent cliff

Source : IMS Global Insight, 2011

2015

Page 15: Patent cliff

Global drug sales at risk from Patent Expiration

Source : Evaluate Pharma Vantage 2010

Page 16: Patent cliff

Forecasted revenues of few blockbuster Post-generification

Source : The Economist,2011

Page 17: Patent cliff

PFIZER – US$30 Lipitor , viagra

Eli lilly- US$13(50%rvnu) Evista , zyprexa &Cymbalta

Takeda- 52%revenue loss Actos

Forest labs- 52%revenue loss Lexapro

Gsk,Novartis,bms,A&Z- 14-40%revenue loss

Fall Down Of Companies Annual Revenue

Source : Price watercoopers,2011

Page 18: Patent cliff

2009-2013 annual patent losses by company

Source : Bio associate Consulting & Management Ltd

Page 19: Patent cliff

0%

5%

10%

15%

20%

25%

30%

R&

D a

s %

of

sale

s

Source: Company data, Goldman Sachs Research estimates

Over $280 billion spent on R&D over last decade

Source : Bioassociate Consulting & Management Ltd

Page 20: Patent cliff

Key drugs in Pipeline

Source : Analyst and company reports,2012

Page 21: Patent cliff

Frequency of NME approvals may come down

Source : US FDA , 2012

2012 : 28NME’s

Page 22: Patent cliff

Big Pharma job cuts announced since 2010

Source : FiercePharma.com,2012, Price watercoopers 2010

Page 23: Patent cliff

Increasing Merges &Acquisitions

2011 –Sanofi-Aventis- Genzyme- -US$20Bn. -Biotech

2011 – Novartis - Aires pharm – US$250Mn -Cystic fibrosis pnemonia2011 – Amgen - Biovex -- US$1Bn -Cancer vaccine Oncovex2009 –Pfizer - Wyeth - US$68 -Fill pipeline, Biologics2009 –Merck -Schering-plough-US$41.1 -18NME’s in pipeline

2009, 563 deals worth US$161.2Bn took place

Page 24: Patent cliff
Page 25: Patent cliff

Source : Pfizer,2012

Contd..

Page 26: Patent cliff

Merges in 2012

Source: business-beacon.com, 2012

Page 27: Patent cliff

Acquisitions in 2012

Source: business-beacon.com, 2012

Page 28: Patent cliff

Contd..

Page 29: Patent cliff

29

For Innovator companies

Patent term extension Provides New drug product exclusivity 30 months stay for ANDA approval

For Generic manufacturers Created “Abbreviated New drug Application” approval

process for generic versions of innovator drugsFile ANDAs with bioequivalence data using innovator

product 180 day exclusivity for first-to-fileCertification regarding each patent listed in the Orange

Book for the product: four certification options

Hatch-Waxman Act-1984

Page 30: Patent cliff

30

Paragraph I

Paragraph II

Paragraph IV

Paragraph III

Patent information has not been filed

Patent has Expired

Patent is invalid or non-infringed by Generic applicant

Patent has NOT expiredbut will expire on a

particular date

FDA may approve ANDA immediately

FDA may approve ANDA on the date that the patent expires

Generic applicant provides notice to patent holder & NDA filer;

entry of the first filermay or may not occur

ANDA Patent certification Options

Page 31: Patent cliff

Source : Orange book

Page 32: Patent cliff

Patent exclusivity & Generic entry regulations

Page 33: Patent cliff

Contd..

Source : DataMonitor,2011:US FDA,2012;

Page 34: Patent cliff

According to IMS Health, generics drugs accounted for 57.7% of prescriptions dispensed five years ago, and close to 75% today

Price of the drugs will be reduced

However, while the generic drug industry will certainly benefit in the short term from the patent cliff

Generics will dominate the market

GENERICS ; US$ 100 Bn/paETHICAL MANUFACTURES ; US$ 720 Bn/paIt is estimated that by 2014 generic market will reach

US$124Bn.

Source : IMS Health, 2012

Page 35: Patent cliff

LEADING GLOBAL GENERIC PLAYERS

Source : Individual company financials 2012

Page 36: Patent cliff

Generics offer Drugs at low cost

Page 37: Patent cliff

Contd..

Source : Blue cross blue shield of michigan

Page 38: Patent cliff

ENTERING “Pharmering Markets”

Source : IMS Health,2011

Page 39: Patent cliff

Contd..

Source : IMS Health,2011

Page 40: Patent cliff

INDIA has large domestic market.

Highest number of US FDA Approved manufacturing Units (74) outside the US.

Clinical trial hub

Less manufacturing cost

High CAGR

Contd..

Page 41: Patent cliff

PATENT WARS

Law suits & legal loopholes are the last resort before a patent cliff for innovators

30 Month marketing stay for brand name drugs as part of patent Infringement litigation, which provides immunity against generics.

Patent ever greening

Page 42: Patent cliff

In the end, the financial future of many pharmaceutical companies will depend on how they manage the transition of many of their brand drugs

to the generic market, as well as on their own efforts to develop novel

therapeutics and diagnostics with significant profit potential, and to adapt to the changing global

business climate.However, while the generic drug industry will

certainly benefit in the short term(upto 2015) from the patent cliff.

CONCLUSION

Page 43: Patent cliff

T H A N K Y O U

Let’s get going ….43

India, China, Russia and Brazil are some of the more obvious novel destinations for

large PHARMA to nest in.

Page 44: Patent cliff

BACK UP SLIDES

Page 45: Patent cliff

During 180 day exclusivity

Page 46: Patent cliff

AG competition typically reduces a first-filer generic’s revenues during the 180 days of marketing exclusivity by approximately 50 percent.

To prevent this loss of revenue, a generic may be willing to delay its entry in return for a brand’s agreement not to launch an authorized generic – that is, a brand’s agreement not to compete with the generic through an AG – during the generic’s 180 days of marketing exclusivity.

Page 47: Patent cliff

7. STRATERGIES TO MINIMIZE THE IMPACT OF PATENT CLIFF

Most obviously, there has been continued investment in new drug discovery and development of a “pipeline” of promising agents that address unmet medical needs and are profitable.

Enhanced advertising over the past decade in an attempt to optimize earnings prior to patent expiration

Page 48: Patent cliff

A number of drug companies have suggested that they will outsource at least some of their manufacturing to places such as Eastern Europe, India, and China, where drug products can be made at significantly less. But Quality issues will become severe.

Some pharmaceutical companies already are entering into agreements with generic manufacturers, licensing them the right to sell “authorized generics” identical to

branded drugs that have gone or will go off patent.

Page 49: Patent cliff

 In an Economist article, it is revealed that Pfizer worked with an American firm in order

to help break apart a 180 day generic exclusivity period, helping the company compete with often

times cheaper generics. These practices have helped to boost sales by over half a billion in the

first half of 2012, taking at least some of the pain of the patent expiration out of the equation

Page 50: Patent cliff
Page 51: Patent cliff
Page 52: Patent cliff
Page 53: Patent cliff
Page 54: Patent cliff
Page 55: Patent cliff

Companies with the biggest cash reserves

Novartis $15 billionRoche $13.5 billion

Johnson & Johnson $13 billionMerck & Co. $10 billion

GlaxoSmithKline $9.5 billion

Page 56: Patent cliff

HYDERABAD: Dr Reddy's Laboratories has agreed to buy the entire equity holding of the Dutch injectable specialty generics manufacturer OctoPlus NV  for 27.39 million euro ( 192 crore) in an all-cash deal.

The Hyderabad-based company said on Monday that OctoPlus' expertise in making improved injectable pharmaceuticals based on proprietary drug delivery technologies and focus on medicine ingredients that are difficult to formulate complement it capabilities.

Source: business-beacon.com, 2012